Document:

exv10w38

 

Exhibit 10.38

Vermillion, Inc.

6611 Dumbarton Circle

Fremont, CA 94555

August 29, 2007

			
	To:  	 	Quest Diagnostics Incorporated

1290 Wall Street West

Lyndhurst, NJ 07071

Re: Registration Rights

Ladies and Gentlemen:

     Reference is made to the Securities Purchase Agreement dated August 23, 2007 (the “2007
Agreement”) by and among Vermillion, Inc. (formerly known as Ciphergen Biosystems, Inc.) and the
Purchasers, including Quest Diagnostics Incorporated. Reference is also made to the Stock Purchase
Agreement dated July 22, 2005 (the “2005 Agreement”) between Ciphergen Biosystems, Inc. and Quest
Diagnostics Incorporated. Reference is made specifically to the Registration Rights found in
Section 4 of the 2005 Agreement and in Section E of the 2007 Agreement.

     We hereby confirm that the defined term “Registrable Securities” in the 2005 Agreement shall
include for all purposes the Shares issued to Quest Diagnostics Incorporated pursuant to the 2007
Agreement and the shares of common stock of Vermillion, Inc. issuable on the exercise of the
warrant issued to Quest Diagnostics Incorporated pursuant to the 2007 Agreement. Quest Diagnostics
Incorporated hereby waives all rights to register any of its shares pursuant to the Registration
Rights contained in the 2007 Agreement. This waiver will also bind any assignees of Quest
Diagnostics’ shares or warrants.

     If the foregoing properly reflects our agreement, please so indicate by acknowledging and
agreeing below.

[Signature Page Follows]

 

 

	 	 	 	 	 
	 	Very truly yours,

VERMILLION, INC.

 	 
	 	By  	/s/
Gail S. Page 	 
	 	 	Name:  	Gail S. Page 	 
	 	 	Title:  	CEO 	 
	 

Acknowledged And Agreed:

QUEST DIAGNOSTICS, INCORPORATED

	 	 	 	 	 
	 	 	 
	By  	/s/
Catherine I. Greany 	 	 
	 	Name: Catherine I. Greany 	 	 	 
	 	Title: VP, M & A and Strategy 	 	 	 
	 

2exv10w40

 

Exhibit 10.40

MEMORIALIZATION AGREEMENT

     This Memorialization Agreement is entered into as of this 12th day of January, 2006, between
Ciphergen Biosystems, Inc., a Delaware corporation (the “Company”), and Quest Diagnostics
Incorporated (the “Purchaser”) (each a “Party” and together the “Parties”).

RECITALS

     1. The Company and the Purchaser have previously entered into a Stock Purchase Agreement dated
as of July 22, 2005 (the “Purchase Agreement”) providing for the sale to the Purchaser of 6,225,000
shares of Common Stock (the “Common Stock”) of the Company and the issuance to the Purchaser of a
Warrant (the “Warrant”) to purchase additional 2,200,000 shares of Common Stock (the “Warrant
Shares”).

     2. The Company and the Purchaser now wish to clarify their original intent with regard to the
terms of the Purchase Agreement and the Warrant.

     NOW, THEREFORE, the Parties agree as follows:

     1. The Warrant may not be exercised for a number of shares that would result in the Purchaser,
after the issuance of any Warrant Shares, owning more than 19.9% of the number of shares of the
Company’s Common Stock outstanding as of the date of such exercise; provided that Purchaser
may, prior to or concurrently with the issuance of any Warrant Shares, sell such number of shares
of Common Stock that, after giving effect to the issuance of the Warrant Shares and such sale,
Purchaser would not own more than 19.9% of the shares of the Common Stock.

     2. The foregoing shall constitute the agreement of the Parties notwithstanding any
language contained in the Purchase Agreement or the Warrant which may be construed to the
contrary.

     3. Governing Law. THIS AGREEMENT SHALL BE GOVERNED IN ALL RESPECTS BY THE LAWS OF THE STATE OF
DELAWARE WITHOUT REGARD TO ITS CONFLICT OF LAWS PRINCIPLES.

     IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly
authorized representatives as of the day and year first written above.

	 	 	 	 	 
	CIPHERGEN BIOSYSTEMS, INC.	 	 
	 
	 	 	 	 
	By:

	 	/s/ Gail S. Page
 

	 	 
	Name:

	 	Gail S. Page	 	 
	Title:

	 	President & CEO	 	 
	 
	 	 	 	 
	QUEST DIAGNOSTICS INCORPORATED	 	 
	 
	 	 	 	 
	By:

	 	/s/ Catherine T. Doherty	 	 
	 

	 	 	 	 
	Name:

	 	Catherine T. Doherty	 	 
	Title:

	 	VP, Office of the Chairmanexv10w47

 

Exhibit 10.47

AMENDMENT TO ASSET PURCHASE AGREEMENT

     This amendment dated as of November 13, 2006 (this “Amendment”) by and between BIO-RAD
LABORATORIES, INC., a Delaware corporation, with offices at 1000 Alfred Nobel Drive, Hercules,
California 94547 (“Buyer”), and CIPHERGEN BIOSYSTEMS, INC., a Delaware corporation, with offices at
6611 Dumbarton Circle, Fremont, California 94555 (“Seller”).

RECITALS

     A. WHEREAS, Buyer and Seller entered into the Asset Purchase Agreement dated as of August 14,
2006 (the “Agreement”); and

     B. WHEREAS, Buyer and Seller desire to amend the Agreement upon the terms and subject to the
conditions set forth herein.

AGREEMENT

     NOW THEREFORE, in consideration of the respective covenants and promises contained herein and
for other good and valuable consideration, the receipt and adequacy of which is hereby
acknowledged, the parties hereto agree as follows:

	1.	 	The definition of “Ancillary Agreements” in Section 1.1 of the Agreement shall be deleted in
its entirety and replaced with the following:
	 
	 	 	“Ancillary Agreements” shall mean the Indemnification Escrow Agreement, Sublease
Agreement, Cross License Agreement, Transition Services Agreement, Stock Purchase Agreement,
Manufacture and Supply Agreement, Sublicense Agreement and UK Letter, substantially in the
forms attached hereto as Exhibits I, J, K, L, M, N, Q and R respectively.
	 
	2.	 	The following shall be inserted at the end of Section 2.1 of the Agreement and at the end of
the first sentence of Section 4.5:
	 
	 	 	“ provided, however, that with respect to the MAS Agreements, as defined in
Section 10.4(a), Seller will not transfer or assign such agreements to Buyer but instead
will sublicense to Buyer certain rights granted to Seller under such agreements pursuant to
the Sublicense Agreement, as defined in Section 3.2(k), and Seller shall continue to perform
its obligations under such agreements, including without limitation its obligation to pay
royalties.”
	 
	3.	 	The following shall be inserted at the end of Section 2.2 of the Agreement:
	 
	 	 	“; provided, however, that the MAS Agreements, as defined in Section
10.4(a), shall not be included in this Section 2.2.”

 

 

	4.	 	The following shall be inserted at the end of Section 3.2 of the Agreement:
	 
	 	 	“(k) Sublicense. Buyer and Seller shall execute and deliver the sublicense
agreement substantially in the form attached hereto as Exhibit Q (the
“Sublicense Agreement”).
	 
	 	 	“(l) UK Letter. Buyer and Seller shall execute and deliver the letter in the form
attached hereto as Exhibit R.”
	 
	5.	 	The following shall be inserted at the end of Section 10.4(a) of the Agreement:
	 
	 	 	“; or (vii) any Liability imposed upon or asserted against Buyer arising out of or relating
to (1) any challenge to the validity or enforceability of the Sublicense Agreement or the
assignment of any or all of the MAS Agreements to Buyer pursuant to Section 10.8 or the
exercise by Buyer of any of its rights or the performance of its obligations under the
Sublicense Agreement or any or all of the MAS Agreements, or (2) any claim that royalties
due to Molecular Analytical Systems, Inc. (“MAS”) or related parties from Buyer under any or
all of the MAS Agreements or the Sublicense Agreement should be based on revenues
attributable to any business or assets other than the Business. The “MAS Agreements” shall
mean any agreement between Seller and MAS, including that certain Exclusive License
Agreement entered into on May 28, 2003 between Seller and MAS (the “Exclusive License
Agreement”).”
	 
	6.	 	The following shall be inserted as a new Section 10.8 of the Agreement:
	 
	 	 	“10.8 Option to Receive Assignment. Buyer and Seller agree that Buyer shall have
(i) an irrevocable option to amend or terminate the Sublicense Agreement and (ii) an
irrevocable option to receive an assignment from Seller (substantially in the form attached
hereto as Exhibit E) of any or all of the MAS Agreements for no additional
consideration; provided, however that Buyer shall only have the option to
terminate the Sublicense Agreement pursuant to clause (i) at such time as it receives the
assignment referenced in clause (ii). In the event Buyer exercises its option to receive
the assignment referenced in clause (ii), (a) Buyer shall thereafter pay royalties to MAS on
its Adjusted Total Revenue (as defined in the Sublicense Agreement) on the terms and
conditions set forth in the Exclusive License Agreement as an assignee thereof and (b)
Seller shall pay royalties to MAS on its Adjusted Total Revenue in accordance with the terms
of the Exclusive License Agreement as if Seller continued to be the licensee thereunder.”
	 
	7.	 	The following shall be inserted as a new Section 10.9 of the Agreement:
	 
	 	 	“10.9 Pre-Closing Employee Costs. The Parties agree that as soon as practicable
after the Closing Date, Buyer shall pay the Rehired Employees their respective salaries and
benefits accrued but unpaid from and including November 1, 2006 through the Closing Date,
and Seller shall reimburse Buyer for fifty percent (50%) of any and all such costs
immediately upon request by Buyer.”
	 
	8.	 	The following shall be inserted as a new Section 10.10 of the Agreement:

2

 

	 
	 	 	“10.10. MAS200 Software License. As soon as practicable after the Closing, Seller
shall seek consent from the licensor to assign or share the MAS200 software license for
immediate use by Buyer as of the Closing Date. To the extent that Seller is unable to
obtain consent to assign or share such license, Seller agrees to reimburse Buyer for the
cost of licensing it directly from the licensor.”
	 
	9.	 	The following shall be inserted as a new Section 10.11 of the Agreement:
	 
	 	 	“10.11 Certain Biomarker Research Agreements. The Parties acknowledge and agree
that the draft biomarker research agreements between Seller and each of Wyeth
Pharmaceuticals and Merck & Co., Inc. involving the use of Seller’s biomarkers for
Alzheimer’s Disease, including all related documents, will be transferred to Buyer, and
Buyer shall directly enter into such agreements with such parties. In the event such
agreements are fully executed, then Seller shall assign such agreements to Buyer. In
connection therewith, Seller shall work with Buyer to allow for Buyer’s access to
information regarding the relevant biomarkers, and Buyer shall provide the data generated
therefrom to Buyer, all on terms to be negotiated in good faith as soon as practicable after
the Closing.
	 
	10.	 	The following shall be inserted as a new Section 10.12 of the Agreement:
	 
	 	 	“10.12. Other Agreements. All agreements that Seller is currently negotiating,
that relate to the Business and that Buyer agrees to accept, along with all related
documents, shall be transferred to Buyer.”
	 
	11.	 	All other terms and conditions of the Agreement remain in full force and effect. This Amendment
may be signed in counterparts, each of which shall be an original and
all of which shall be read together as constituting a single document.

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed on their
respective behalf, by their respective officers thereunto duly authorized, all as of the day and
year first above written.

	 	 	 	 	 	 	 	 	 	 	 
	CIPHERGEN BIOSYSTEMS, INC.	 	 	 	BIO-RAD LABORATORIES, INC.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Debra Young
	 	 	 	By:
	 	/s/ Norman Schwartz	 	 
	Name:

	 	 

Debra Young
	 	 
	 	Name:
	 	 

Norman Schwartz
	 	 
	Title:

	 	CFO & VP of Finance
	 	 	 	Title:
	 	President	 	 

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00130-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00130-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00130-of-00352.parquet"}]]